Canada’s medical cannabis sector punches well above its weight on the world stage. While many countries still debate legal access, Canadian firms export high-grade products to dozens of markets and help set standards for regulated production. Tilray Brands Inc (TSE: TLRY) (NASDAQ: TLRY) (FRA: 2HQ) aims to strengthen its position in this space through its recent acquisition of HelloMD’s Canadian assets.
Tilray completed the court-supervised purchase of HelloMD’s Canadian medical cannabis operations on Jun 29. The deal adds a digital healthcare platform that connects patients with practitioners for telehealth consultations, education and personalised guidance.
The move creates a more vertically integrated model for Tilray in Canada. It links the company’s cultivation and clinical know-how with direct-to-patient tools. Executives say this will let patients enter care earlier through better education and support. It also strengthens Tilray’s global medical platform, which already includes operations in Europe, Australia and beyond. Financial terms remain undisclosed.
“I believe Tilray has the expertise, infrastructure, and drive to expand the platform’s reach and impact,” said HelloMD CEO Larry Lisser in a news release from Tilray, “benefiting patients for years to come.”
Critics note that this is not a game-changer on its own though. Canada’s medical channel has shrunk since adult-use legalisation began, as many patients shifted to recreational products. Adding digital infrastructure helps Tilray compete and gather insights, but it does not fix broader pricing pressure or slow growth in the home market. The acquisition fits Tilray’s pattern of buying distressed assets, but success will depend on execution and actual patient uptake going forward.
$TilrayArmy🍀💰 – Today, $TLRY💰🍀 announced that it will acquire HelloMD’s Canadian assets, subject to court approval. Financial terms of the deal were not disclosed.
Why is this a positive for $TLRY💰🍀 ?
* Direct access to…
— OVI (@OVI_USA) June 29, 2026
Read more: Washington warns World Cup goers that its cannabis is more dank than they’re used to
Stock struggles despite positive indicators
Tilray’s shares have fallen more than 50 per cent year-to-date. Investors appear wary despite some operational progress. The stock trades near the lower end of its 52-week range amid ongoing losses, execution risks and a tough industry backdrop.
Q1 fiscal results delivered record net revenue of about US$210 million, up 5 per cent year-over-year. The company posted a small net income of US$1.5 million versus a large prior loss with adjusted EBITDA rising 9 per cent to US$10 million. Canadian adult-use sales grew and international cannabis revenue increased. These figures built on earlier efforts to cut costs and improve cash flow.
However, analysts remain cautious. An investment research piece from The Motley Fool in March argued against buying the stock, citing persistent losses, modest revenue growth and uncertainty around future markets. Even solid quarters fail to impress when the bigger picture shows heavy reliance on regulatory tailwinds that may take time to pan out.
More broadly, American rescheduling momentum offers some hope for Tilray’s medical future south of the border. Easier federal rules could open a massive market. However, many observers view this as uncertain and potentially overhyped.
For now, the development looks more like a long-term possibility than an immediate catalyst. It may not prove significant enough to transform Tilray’s outlook in the near term.
Read more: Canada’s top cannabis lobby group suspends operations indefinitely
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
